Navigation Links
Drug studied as possible treatment for spinal injuries
Date:11/19/2009

searchers subjected spinal cord tissue to stresses that mimic what happens in a compression injury, which stretches nerves. Then they treated the damaged axons with 4-aminopyridine-3-methyl hydroxide.

The compound is a derivative of the drug 4-aminopyridine, used primarily as a research tool and also to manage symptoms of multiple sclerosis.

The axons of each nerve are sheathed in a thick insulating lipid layer, called myelin, which enables the transmission of signals without short circuiting, much like the insulation surrounding electrical wires. Spinal cord trauma damages the myelin sheath, exposing "fast potassium channels" that are embedded in the axons and are critical for transmitting nerve impulses.

The researchers confirmed previous circumstantial evidence suggesting injury causes the myelin insulation to recede, exposing the channels and impairing signal transmission. Laboratory and imaging techniques revealed the exposed channels in damaged axons.

The researchers also discovered that 4-aminopyridine-3-methyl hydroxide is a "potassium channel blocker," using a sophistic laboratory technique called "patch clamp" to measure signal conduction. Findings confirmed that the compound prevents the exposed channels from leaking electrical current and enhances nerve conduction in segments of the damaged spinal cord.

The compound could make it possible to sidestep spinal cord damage by enabling axons to transmit signals as though they were still sheathed in myelin, Shi said.

Nerves transmit signals through a series of rapid electrical pulses, or "action potentials." For proper nerve function, the time gap between pulses must be as brief as possible. However, 4-aminopyridine has been shown to lengthen the gap, or "refractory period," between pulses. The researchers found that 4-aminopyridine-3-methyl hydroxide restores function without affecting the refractory period. As a result, the damaged nerves perform more lik
'/>"/>

Contact: Emil Venere
venere@purdue.edu
765-494-4709
Purdue University
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Feline virus, antiviral drug studied to understand drug resistance
2. Gulf of Mexico dead zone to be studied by University of Texas at Austin marine scientists
3. Silicons effect on sunflowers studied
4. Alternatives to ozone-depleting pesticide studied
5. New roadside beautification concept studied
6. Complex ocean behavior studied with artificial upwelling
7. Potential new herpes therapy studied
8. Hispanic women and breast cancer: An understudied group
9. Possible hepatitis C vaccine
10. Study by Pittsburgh researchers identifies possible vaccine target for chlamydia
11. Study reveals possible genetic risk for fetal alcohol disorders
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug studied as possible treatment for spinal injuries
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation ... largest exhibition for service robots ever held in ... takes place on May 11-13, 2015 at the ... exhibitors for the event include: Acorn Product Development; ... EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya ...
(Date:3/12/2015)... MOUNTAIN VIEW, Calif. , March 12, 2015 ... EDTLOCATION:Online, with Complimentary Registration here: http://bit.ly/1G7Os0L . ... Program Manager Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... future in order to compete in several different ... the market is currently witnessing an uptrend. ...
(Date:3/10/2015)... , March 10, 2015   Tute Genomics , ... been selected by next-generation sequencing company PrimBio Research ... exome and targeted gene panel interpretation. PrimBio, ... adopted the most current technologies to support the work ... The company offers two types of exome sequencing services: ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3
... lacking a special protein found only in germ-line cells ... to a new study from researchers at the University ... of Human Reproduction in Penn's Center for Research in ... investigations point the way to a new type of ...
... In a recent study published in the Journal of ... to play a purely structural and inert role in ... Using antagonists for this molecule, the researchers were able ... drug treatment. , The research appears as the "Paper ...
... of neuroscientists have been indoctrinated into believing that ... by a communication network of brain cells, or ... message called a neurotransmitter. Either neurons release a ... an electrical discharge and enhancing brain activity, or ...
Cached Biology News:Of mice and men's (and women's) contraceptives 2New polysaccharide may help combat multidrug resistance in cancer 2Researchers make surprise discovery that some neurons can transmit three signals at once 2Researchers make surprise discovery that some neurons can transmit three signals at once 3
(Date:3/25/2015)... BLOOMINGTON, MN (PRWEB) March 25, 2015 ... a breakthrough in nanoparticle technology that will enable ... and many other diseases with a simple breath ... ahead on the U.S. Food and Drug Administration ... 2016 launch of the innovative Nanoparticle Biomarker Tagging ...
(Date:3/25/2015)... /CNW/ - The Gairdner Foundation is pleased to ... recognizing some of the most significant medical discoveries ... the world,s most esteemed medical research prizes, the ... a $100,000 (CDN) prize to each scientist for their work. ... and innovation across the country, inspiring the next ...
(Date:3/25/2015)... 2015 Proove Biosciences , a ... to announce the success of their commercially supported symposium, ... to Optimize the Management of Pain, at the 31st ... Harbor, Maryland on Thursday, March 19th, 2015. ... President Lynn Webster , M.D., former Florida Society ...
(Date:3/25/2015)... 25, 2015 Oxis International, Inc. (OXIS) (OXI.PA) ... commercialization, announced today Oxis CEO Tony Cataldo ... 2015 at 4:15pm EST to update shareholders and other ...     Oxis Chairman and CEO Tony ... been very exciting for Oxis and our shareholders. There ...
Breaking Biology Technology:Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 32015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 22015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 32015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 42015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 52015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 62015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 72015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 8Proove Biosciences Hosts Symposium on Incorporating Genetic Testing to Optimize the Management of Pain 2Oxis Biotech Inc. Announces Corporate Update Conference Call for March 31 2
... (OTC:,SPOM - News), a leading developer of biosensor and ... that it,has appointed Med Tech and Med Care Associates ... market. , Med Tech and ... healthcare industry and operate with manufacturers,of medical products and ...
... Md., Feb. 17 Human Genome Sciences, Inc. (Nasdaq: ... GSK ) has initiated a Phase 3 ... tolerability of Syncria (R) (albiglutide) in the long-term ... result, HGS will receive a $9 million milestone payment ...
... at the 19th Conference of the Asian Pacific ... Demonstrated Favorable Pharmacokinetics and Significant Reduction in Viral ... privately held biopharmaceutical company, today announced results from ... a controlled release version of nitazoxanide in the ...
Cached Biology Technology:SPO Medical Appoints New US Sales Rep Groups 2SPO Medical Appoints New US Sales Rep Groups 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 2Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 4Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C 2Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C 3Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C 4
... designed to rapidly and reliably amplify unknown ... Technology. APAgene provides hassle-free, ready-to use components, ... ingredients are provided in each kit. The ... gap filling, localized cloning of genomic DNA, ...
Protein YIPF6 (YIP1 family member 6). [Source:Uniprot/SWISSPROT;Acc:Q96EC8] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Collected from animals of U.S. origin.Collected from animals of U.S. origin. *Can be used in cell growth studies and immunoassays. *Sterility tested, * Mycoplasma tested upon request, *Endoto...
...
Biology Products: